Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute
to hypoxemic respiratory failure, the most common cause of death, in patients with COVID …

Introduction A hypercoagulable condition was described in patients with coronavirus
disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing …

This study investigates the association between the treatment with heparin and mortality in
patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April …

Background Heparin, in addition to its anticoagulant properties, has anti-inflammatory and
potential anti-viral effects, and may improve endothelial function in patients with Covid-19 …

Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients
hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of …

Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is responsible of
variable clinical manifestations, ranging from no symptoms to severe pneumonia with acute …

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with
CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of …

Background Heparin administration in COVID-19 patients is recommended by expert
consensus, although evidence about dosage, duration and efficacy are limited. We aim to …

Background: Antithrombotic treatment, including low molecular weight heparin (LMWH) or
unfractionated heparin (UFH), has been proposed as a potential therapy for coronavirus …